CoChat
Sign Up
Cited by 429

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

Siena, Salvatore, Sartore-Bianchi, Andrea, Di Nicolantonio, Federica, Balfour, Julia, Bardelli, Alberto·2009·JNCI: Journal of the National Cancer Institute
DOI 10.1093/jnci/djp280PMC PMC2758310
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djp280

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 25 references

Research works printed but not linked: 109

  1. Yarden, 2001, Untangling the ErbB signalling network, Nat Rev Mol Cell Biol., 2, 127, 10.1038/35052073 · DOI · Paper page
  2. Scaltriti, 2006, The epidermal growth factor receptor pathway: a model for targeted therapy, Clin Cancer Res., 12, 5268, 10.1158/1078-0432.CCR-05-1554 · DOI · Paper page
  3. Harari, 2004, Epidermal growth factor receptor inhibition strategies in oncology, Endocr Relat Cancer, 11, 689, 10.1677/erc.1.00600 · DOI · Paper page
  4. Nicholson, 2001, EGFR and cancer prognosis, Eur J Cancer, 37, S9, 10.1016/S0959-8049(01)00231-3 · DOI
  5. Mackenzie, 2005, A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer, Invest New Drugs, 23, 165, 10.1007/s10637-005-5862-9 · DOI
  6. Santoro, 2008, A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer, Ann Oncol, 19, 1888, 10.1093/annonc/mdn401 · DOI
  7. Sobrero, 2008, EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer, J Clin Oncol, 26, 2311, 10.1200/JCO.2007.13.1193 · DOI
  8. Van Cutsem, 2007, Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial [abstract 4000], J Clin Oncol, 25, 10.1200/jco.2007.25.18_suppl.4000 · DOI
  9. Bokemeyer, 2007, Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study [abstract 4035], J Clin Oncol, 25, 10.1200/jco.2007.25.18_suppl.4035 · DOI
  10. Saltz, 2004, Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor, J Clin Oncol, 22, 1201, 10.1200/JCO.2004.10.182 · DOI · Paper page
  11. Van Cutsem, 2007, Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer, J Clin Oncol, 25, 1658, 10.1200/JCO.2006.08.1620 · DOI · Paper page
  12. Peeters, 2008, Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): pooled safety results [abstract 4064], J Clin Oncol, 26, 10.1200/jco.2008.26.15_suppl.4064 · DOI
  13. Siena, 2008, Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): pooled safety data [abstract 4034], J Clin Oncol, 26, 10.1200/jco.2008.26.15_suppl.4034 · DOI
  14. Tol, 2009, Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer, N Engl J Med, 360, 563, 10.1056/NEJMoa0808268 · DOI
  15. Hecht, 2007, Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer, Cancer, 110, 980, 10.1002/cncr.22915 · DOI
  16. O’Neil, 2007, High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history, J Clin Oncol, 25, 3644, 10.1200/JCO.2007.11.7812 · DOI
  17. Chung, 2008, Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose, N Engl J Med, 358, 1109, 10.1056/NEJMoa074943 · DOI · Paper page
  18. Chung, 2005, Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry, J Clin Oncol, 23, 1803, 10.1200/JCO.2005.08.037 · DOI · Paper page
  19. Mitchell, 2007, Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: an updated analysis [abstract 4082], J Clin Oncol, 25
  20. Perez-Soler, 2004, Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer, J Clin Oncol, 22, 3238, 10.1200/JCO.2004.11.057 · DOI
  21. Parra, 2004, Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer, Br J Cancer, 91, 208, 10.1038/sj.bjc.6601923 · DOI
  22. Bokemeyer, 2009, Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer, J Clin Oncol, 27, 663, 10.1200/JCO.2008.20.8397 · DOI
  23. McCubrey, 2006, Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance, Adv Enzyme Regul, 46, 249, 10.1016/j.advenzreg.2006.01.004 · DOI
  24. Bos, 1989, ras oncogenes in human cancer: a review, Cancer Res., 49, 4682
  25. Barault, 2008, Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers, Int J Cancer, 122, 2255, 10.1002/ijc.23388 · DOI
  26. Benvenuti, 2007, Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies, Cancer Res., 67, 2643, 10.1158/0008-5472.CAN-06-4158 · DOI · Paper page
  27. Lievre, 2006, KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res., 66, 3992, 10.1158/0008-5472.CAN-06-0191 · DOI · Paper page
  28. Frattini, 2005, Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer, Cancer Res., 65, 11227, 10.1158/0008-5472.CAN-05-2780 · DOI
  29. Freeman, 2008, Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone, Clin Colorectal Cancer, 7, 184, 10.3816/CCC.2008.n.024 · DOI
  30. Velho, 2005, The prevalence of PIK3CA mutations in gastric and colon cancer, Eur J Cancer, 41, 1649, 10.1016/j.ejca.2005.04.022 · DOI
  31. Perrone, 2009, PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients, Ann Oncol, 20, 84, 10.1093/annonc/mdn541 · DOI · Paper page
  32. Tol, 2009, BRAF mutation in metastatic colorectal cancer [letter to editor], N Engl J Med, 361, 98, 10.1056/NEJMc0904160 · DOI · Paper page
  33. Fearon, 1990, A genetic model for colorectal tumorigenesis, Cell., 61, 759, 10.1016/0092-8674(90)90186-I · DOI · Paper page
  34. Andreyev, 2001, Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study, Br J Cancer, 85, 692, 10.1054/bjoc.2001.1964 · DOI
  35. Zauber, 2003, Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas, Mol Pathol, 56, 137, 10.1136/mp.56.3.137 · DOI
  36. Artale, 2008, Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer, J Clin Oncol, 26, 4217, 10.1200/JCO.2008.18.7286 · DOI · Paper page
  37. Etienne-Grimaldi, 2008, K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy, Clin Cancer Res., 14, 4830, 10.1158/1078-0432.CCR-07-4906 · DOI
  38. Oudejans, 1991, Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver, Int J Cancer, 49, 875, 10.1002/ijc.2910490613 · DOI
  39. Esteller, 2001, K-ras and p16 aberrations confer poor prognosis in human colorectal cancer, J Clin Oncol, 19, 299, 10.1200/JCO.2001.19.2.299 · DOI
  40. Bazan, 2002, Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype, Ann Oncol, 13, 1438, 10.1093/annonc/mdf226 · DOI
  41. Markowitz, 1995, Mutant K-ras oncogenes in colon cancers do not predict patient's chemotherapy response or survival, Clin Cancer Res., 1, 441
  42. Dix, 1994, The common molecular genetic alterations in Dukes’ B and C colorectal carcinomas are not short-term prognostic indicators of survival, Int J Cancer, 59, 747, 10.1002/ijc.2910590606 · DOI
  43. Morrin, 1994, Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance, Gut, 35, 1627, 10.1136/gut.35.11.1627 · DOI
  44. Karapetis, 2008, K-ras mutations and benefit from cetuximab in advanced colorectal cancer, N Engl J Med, 359, 1757, 10.1056/NEJMoa0804385 · DOI · Paper page
  45. De Roock, 2008, KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab, Ann Oncol, 19, 508, 10.1093/annonc/mdm496 · DOI · Paper page
  46. Khambata-Ford, 2007, Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab, J Clin Oncol, 25, 3230, 10.1200/JCO.2006.10.5437 · DOI · Paper page
  47. Lievre, 2008, KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab, J Clin Oncol, 26, 374, 10.1200/JCO.2007.12.5906 · DOI
  48. Philip, 2007, Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study [2007 ASCO Meeting abstracts], J Clin Oncol, 25
  49. Sempere, 2008, Shining the spotlight on shed KRAS in pancreatic cancer, Cancer Biol Ther, 7, 361, 10.4161/cbt.7.3.5582 · DOI
  50. Pao, 2005, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib, PLoS Med, 2, 10.1371/journal.pmed.0020017 · DOI
  51. Massarelli, 2007, KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer, Clin Cancer Res., 13, 2890, 10.1158/1078-0432.CCR-06-3043 · DOI
  52. Eberhard, 2005, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib, J Clin Oncol, 23, 5900, 10.1200/JCO.2005.02.857 · DOI
  53. Bianco, 2003, Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors, Oncogene, 22, 2812, 10.1038/sj.onc.1206388 · DOI
  54. Sartore-Bianchi, 2009, PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies, Cancer Res., 69, 1851, 10.1158/0008-5472.CAN-08-2466 · DOI · Paper page
  55. Razis, 2008, Potential value of PTEN in predicting cetuximab response in colorectal cancer. An exploratory study, BMC Cancer, 8, 234, 10.1186/1471-2407-8-234 · DOI
  56. Yuan, 2008, Cantley LC. PI3K pathway alterations in cancer: variations on a theme, Oncogene, 27, 5497, 10.1038/onc.2008.245 · DOI · Paper page
  57. Bianco, 2008, Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs, Br J Cancer, 98, 923, 10.1038/sj.bjc.6604269 · DOI
  58. Benvenuti, 2008, PIK3CA cancer mutations display gender and tissue specificity patterns, Hum Mutat, 29, 284, 10.1002/humu.20648 · DOI
  59. Shia, 2005, Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study, Mod Pathol, 18, 1350, 10.1038/modpathol.3800417 · DOI
  60. Scartozzi, 2004, Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies, J Clin Oncol, 22, 4772, 10.1200/JCO.2004.00.117 · DOI
  61. Francoual, 2006, EGFR in colorectal cancer: more than a simple receptor, Ann Oncol, 17, 962, 10.1093/annonc/mdl037 · DOI
  62. Personeni, 2005, Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer, Semin Oncol, 32, S59, 10.1053/j.seminoncol.2005.04.029 · DOI
  63. Taron, 2005, Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas, Clin Cancer Res., 11, 5878, 10.1158/1078-0432.CCR-04-2618 · DOI
  64. Sequist, 2007, Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing, Oncologist, 12, 90, 10.1634/theoncologist.12-1-90 · DOI
  65. Barber, 2004, Somatic mutations of EGFR in colorectal cancers and glioblastomas, N Engl J Med, 351, 2883, 10.1056/NEJM200412303512724 · DOI
  66. Lenz, 2006, Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines, J Clin Oncol, 24, 4914, 10.1200/JCO.2006.06.7595 · DOI
  67. Moroni, 2005, Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer, Ann Oncol, 16, 1848, 10.1093/annonc/mdi356 · DOI
  68. Press, 2008, Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer, Cancer Res., 68, 3037, 10.1158/0008-5472.CAN-07-2718 · DOI
  69. Goncalves, 2008, A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment, BMC Cancer, 8, 169, 10.1186/1471-2407-8-169 · DOI
  70. Graziano, 2008, Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer, J Clin Oncol, 26, 1427, 10.1200/JCO.2007.12.4602 · DOI
  71. Wang, 2007, Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma, Clin Cancer Res., 13, 3597, 10.1158/1078-0432.CCR-06-2601 · DOI
  72. Garm Spindler, 2009, The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer, Ann Oncol, 20, 879, 10.1093/annonc/mdn712 · DOI
  73. Zhang, 2006, Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with cetuximab, Pharmacogenet Genomics, 16, 475, 10.1097/01.fpc.0000220562.67595.a5 · DOI
  74. Ooi, 2004, Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study, Mod Pathol, 17, 895, 10.1038/modpathol.3800137 · DOI
  75. Sartore-Bianchi, 2007, Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab, J Clin Oncol, 25, 3238, 10.1200/JCO.2007.11.5956 · DOI
  76. Personeni, 2008, Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study, Clin Cancer Res., 14, 5869, 10.1158/1078-0432.CCR-08-0449 · DOI
  77. Moroni, 2008, EGFR FISH in colorectal cancer: what is the current reality?, Lancet Oncol, 9, 402, 10.1016/S1470-2045(08)70109-8 · DOI
  78. Harbison, 2008, In reply, J Clin Oncol, 26, 2230, 10.1200/JCO.2008.16.0473 · DOI
  79. Finocchiaro, 2007, EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer [abstract 4021], J Clin Oncol, 25, 10.1200/jco.2007.25.18_suppl.4021 · DOI
  80. Ellis, 2004, Angiogenesis and its role in colorectal tumor and metastasis formation, Semin Oncol, 31, 3, 10.1053/j.seminoncol.2004.11.028 · DOI
  81. Ellis, 2004, Epidermal growth factor receptor in tumor angiogenesis, Hematol Oncol Clin North Am., 18, 1007, 10.1016/j.hoc.2004.06.002 · DOI
  82. Ciardiello, 2006, Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy, Ann Oncol, 17
  83. Ciardiello, 2004, Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy, Clin Cancer Res., 10, 784, 10.1158/1078-0432.CCR-1100-03 · DOI · Paper page
  84. Tortora, 2008, Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications, Nat Clin Pract Oncol, 5, 521, 10.1038/ncponc1161 · DOI
  85. Bianco, 2008, Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells, Clin Cancer Res., 14, 5069, 10.1158/1078-0432.CCR-07-4905 · DOI · Paper page
  86. Nagashima, 2007, EGFR, Cox-2, and EGF polymorphisms associated with progression-free survival of EGFR-expressing metastatic colorectal cancer patients treated with single-agent cetuximab (IMCL-0144) [abstract 4129], J Clin Oncol, 25, 10.1200/jco.2007.25.18_suppl.4129 · DOI
  87. Wang, 2009, Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9, Mol Biol Cell., 20, 791, 10.1091/mbc.E08-07-0732 · DOI
  88. Smakman, 2005, Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases, Clin Cancer Res., 11, 41, 10.1158/1078-0432.41.11.1 · DOI
  89. Pai, 2002, Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy, Nat Med, 8, 289, 10.1038/nm0302-289 · DOI
  90. Scartozzi, 2007, Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy, J Clin Oncol, 25, 3930, 10.1200/JCO.2007.11.5022 · DOI
  91. Zhang, 2007, FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab, J Clin Oncol, 25, 3712, 10.1200/JCO.2006.08.8021 · DOI
  92. Negri, 2007, Immunoglobulin G fragment C receptor polymorphisms and clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with cetuximab-based therapy. Abstract presented at: 14th ECCO; September 23–27, 2007; Barcelona, Spain, 96
  93. Lopez-Albaitero, 2007, Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer, Arch Otolaryngol Head Neck Surg, 133, 1277, 10.1001/archotol.133.12.1277 · DOI
  94. Oden-Gangloff, 2009, TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy, Br J Cancer, 100, 1330, 10.1038/sj.bjc.6605008 · DOI
  95. Berlin, 2007, Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of five clinical trials [abstract 4134], J Clin Oncol, 25, 10.1200/jco.2007.25.18_suppl.4134 · DOI
  96. Tejpar, 2007, Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data [abstract 4037], J Clin Oncol, 25, 10.1200/jco.2007.25.18_suppl.4037 · DOI
  97. Tejpar, 2008, Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): the EVEREST experience (preliminary data) [abstract 4001], J Clin Oncol, 26, 10.1200/jco.2008.26.15_suppl.4001 · DOI
  98. Rowinsky, 2004, Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer, J Clin Oncol, 22, 3003, 10.1200/JCO.2004.11.061 · DOI
  99. Perez-Soler, 2005, Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?, J Clin Oncol, 23, 5235, 10.1200/JCO.2005.00.6916 · DOI
  100. Allan, 2005, Nimotuzumab: evidence of clinical benefit without rash, Oncologist, 10, 760, 10.1634/theoncologist.10-9-760 · DOI
  101. Crombet, 2004, Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients, J Clin Oncol, 22, 1646, 10.1200/JCO.2004.03.089 · DOI
  102. Tejpar, 2007, Magnesium wasting associated with epidermal-growth factor receptor-targeting antibodies in colorectal cancer: a prospective study, Lancet Oncol, 85, 387, 10.1016/S1470-2045(07)70108-0 · DOI
  103. Vincenzi, 2008, Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome, Clin Cancer Res., 14, 4219, 10.1158/1078-0432.CCR-08-0077 · DOI
  104. Vincenzi, 2006, Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients, Ann Oncol, 17, 835, 10.1093/annonc/mdl031 · DOI
  105. Allegra, 2009, American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy, J Clin Oncol, 27, 2091, 10.1200/JCO.2009.21.9170 · DOI · Paper page
  106. Razis, 2006, Predictive markers for the treatment of colorectal cancer with cetuximab [O Meeting abstract 13500], J Clin Oncol, 24
  107. Siena, 2007, Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab, Br J Cancer, 97, 1469, 10.1038/sj.bjc.6604053 · DOI
  108. Anonymous, FDA adds KRAS testing info to Vectibix, Erbitux Labels (Press Release, Genome Web News)
  109. Baker, 2008, Evaluation of tumor gene expression and K-Ras mutations in FFPE tumor tissue as predictors of response to cetuximab in metastatic colorectal cancer [abstract 3512], J Clin Oncol, 26, 10.1200/jco.2008.26.15_suppl.3512 · DOI

Cited by

Sorted by citations

See all 429

Metadata

Authors
Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., & Bardelli, A.
Venue
JNCI: Journal of the National Cancer Institute
Publisher
Oxford University Press (OUP)
Published
2009-10-07
Volume
101
Issue
19
Pages
1308-1324
ISSN
  • 1460-2105
  • 0027-8874
DOI
10.1093/jnci/djp280
PMC
PMC2758310
Cited by
429
References
25
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review